Bristol-Myers Squibb's (BMY) Opdivo for Treatment of Esophageal Cancer Granted Orphan Drug Status by FDA
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Bristol-Myers Squibb's (NYSE: BMY) Opdivo for treatment of esophageal cancer was granted orphan drug status by the FDA. The generic name is nivolumab.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Opdivo sBLA as Treatment for Adv. Bladder Cancer
- Global Blood Therapeutics (GBT) Chief Medical Officer Ramos Retired
- Clayton Williams Energy (CWEI) Enters Agreement to Sell Giddings Area Assets in $400M Deal; Names New COO
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!